search
Back to results

Soluble Corn Fiber Supplementation for Asthma

Primary Purpose

Asthma in Children

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Soluble Corn Fiber
Sponsored by
Phoenix Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma in Children

Eligibility Criteria

6 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of asthma
  • Fractional excretion of exhaled nitric oxide (FeNO) > 50 ppb OR a history of environmental allergies
  • No emergency department or hospital visits for asthma in the past 3 months
  • No systemic corticosteroids in the past 1 month
  • Ability to consume a liquid drink of SCF or placebo
  • Ability to return for a 4-6 week follow-up visit
  • No special or unique diet as determined by PI/CO-Is.

Exclusion Criteria:

  • Cystic fibrosis
  • Bronchiectasis
  • Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks.

Sites / Locations

  • Phoenix Childrens Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

PROMOTIR soluble corn fiber

Malodextrin

Arm Description

Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.

Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.

Outcomes

Primary Outcome Measures

Asthma symptoms
Asthma Control Questionnaire

Secondary Outcome Measures

Change in Serum Short Chain Fatty Acids
Change in nasal wash Th2 gene expression
Alpha and beta diversity in participants' nasal microbiome
Alpha and beta diversity in participants' stool microbiome

Full Information

First Posted
September 12, 2018
Last Updated
March 28, 2023
Sponsor
Phoenix Children's Hospital
Collaborators
Northern Arizona University, Flinn Foundation, Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT03673618
Brief Title
Soluble Corn Fiber Supplementation for Asthma
Official Title
Soluble Corn Fiber Supplementation for Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Phoenix Children's Hospital
Collaborators
Northern Arizona University, Flinn Foundation, Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Studies of the importance of the human microbiome have demonstrated that microbial metabolites of fermentation of our dietary products (e.g. dietary fiber) have a multitude of health benefits. The investigators aim to determine whether supplementation of asthmatic children with soluble corn fiber alongside standard of care reduces airway inflammation driven by the gut microbial metabolites acetate, propionate, or butyrate (short chain fatty acids).
Detailed Description
Asthma is a complex inflammatory disease of the airways that is estimated to affect 300 million people worldwide. Incidence of asthma is steadily increasing in Western populations; an additional 100 million asthma diagnoses are anticipated by the year 2025. Asthma is a multifactorial disease affected by genetic and environmental factors. One major and potentially modifiable environmental factor is the Western diet. The Western diet influences the microbiome, which in turn, may influence inflammatory airway diseases via a gut microbiome-airway connection. The investigators hypothesize that prebiotic dietary fiber supplementation leads to increased circulating short chain fatty acid production and improvement in asthma disease activity. The investigators will recruit 20 children, ages 6-17 years old, with asthma from the Severe Asthma Clinic or General Pulmonary Clinic at Phoenix Children's Hospital. Participants will be randomly assigned (1:1) using a random number generator to ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage or placebo (malodextrin in a similar fruit-flavored beverage) as previously described. Participants will be asked to consume the prebiotic soluble corn fiber (or placebo) for 4 weeks alongside their normal diet and normal asthma treatments. Blood will be collected pre- and post-fiber intervention to measure baseline and post-intervention circulating SCFAs. Stool samples and nasal wash will be collected for microbiome and immune analysis pre- and post- fiber consumption. Nasal washes will be collected pre- and post-fiber consumption to measure inflammatory patterns.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma in Children

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
A study pharmacist will provide soluble corn fiber or a placebo (malodextrin) in identical packets to be dispensed in identical fruit-flavored beverage
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PROMOTIR soluble corn fiber
Arm Type
Experimental
Arm Description
Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
Arm Title
Malodextrin
Arm Type
Placebo Comparator
Arm Description
Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
Intervention Type
Drug
Intervention Name(s)
Soluble Corn Fiber
Intervention Description
Fiber or placebo
Primary Outcome Measure Information:
Title
Asthma symptoms
Description
Asthma Control Questionnaire
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Change in Serum Short Chain Fatty Acids
Time Frame
Before treatment period and after treatment for 4 weeks
Title
Change in nasal wash Th2 gene expression
Time Frame
Before treatment period and after treatment for 4 weeks
Title
Alpha and beta diversity in participants' nasal microbiome
Time Frame
Before treatment period and after treatment for 4 weeks
Title
Alpha and beta diversity in participants' stool microbiome
Time Frame
Before treatment period and after treatment for 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of asthma Fractional excretion of exhaled nitric oxide (FeNO) > 50 ppb OR a history of environmental allergies No emergency department or hospital visits for asthma in the past 3 months No systemic corticosteroids in the past 1 month Ability to consume a liquid drink of SCF or placebo Ability to return for a 4-6 week follow-up visit No special or unique diet as determined by PI/CO-Is. Exclusion Criteria: Cystic fibrosis Bronchiectasis Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks.
Facility Information:
Facility Name
Phoenix Childrens Hospital
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85016
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Soluble Corn Fiber Supplementation for Asthma

We'll reach out to this number within 24 hrs